SwePub
Sök i LIBRIS databas

  Utökad sökning

WFRF:(Forsberg Lars)
 

Sökning: WFRF:(Forsberg Lars) > Once-only colonosco...

LIBRIS Formathandbok  (Information om MARC21)
FältnamnIndikatorerMetadata
00006191naa a2200517 4500
001oai:DiVA.org:liu-187549
003SwePub
008220825s2022 | |||||||||||000 ||eng|
009oai:prod.swepub.kib.ki.se:150324585
0247 a https://urn.kb.se/resolve?urn=urn:nbn:se:liu:diva-1875492 URI
0247 a https://doi.org/10.1016/S2468-1253(21)00473-82 DOI
0247 a http://kipublications.ki.se/Default.aspx?queryparsed=id:1503245852 URI
040 a (SwePub)liud (SwePub)ki
041 a engb eng
042 9 SwePub
072 7a ref2 swepub-contenttype
072 7a art2 swepub-publicationtype
1001 a Forsberg, Annau Karolinska Institutet,Soder Sjukhuset, Sweden4 aut
2451 0a Once-only colonoscopy or two rounds of faecal immunochemical testing 2 years apart for colorectal cancer screening (SCREESCO): preliminary report of a randomised controlled trial
264 1b ELSEVIER INC,c 2022
338 a print2 rdacarrier
500 a Funding Agencies|Swedish regions, County Council; Swedish Cancer Society; Eiken Chemical; Aleris Research and Development Fund; Regional Cancer Center Mellansverige
520 a Background Screening for colorectal cancer is done with lower gastrointestinal endoscopy or stool-based tests. There is little evidence from randomised trials to show primary colonoscopy reduces mortality in colorectal cancer We aimed to investigate the effect of screening with once-only colonoscopy or two rounds of faecal immunochemical test screening on colorectal cancer mortality and incidence. Methods We did a randomised controlled trial in Sweden (SCREESCO). Residents in 18 of 21 regions who were age 60 years in the year of randomisation were identified from a population register maintained by the Swedish Tax Agency. A statistician with no further involvement in the trial used a randomised block method to assign individuals to once-only colonoscopy, two rounds of faecal immunochemical testing (OC-Sensor; 2 years apart), or a control group (no intervention; standard diagnostic pathways), in a ratio of 1:6 for colonoscopy versus control and 1:2 for faecal immunochemical testing versus control. Masking was not possible due to the nature of the trial. The primary endpoints of the trial are colorectal cancer mortality and colorectal cancer incidence. Here, we report preliminary participation rates, baseline findings, and adverse events from March, 2014, to December, 2020, in the two intervention groups after completion of recruitment and screening, up to the completion of the second faecal immunochemical testing round. Analyses were done in the intention-to-screen population, defined as all individuals who were randomly assigned to the respective study group. This study is registered with Clinical Trials.gov, NCT02078804. Findings Between March 1, 2014, and Dec 31, 2020, 278 280 people were induded in the study; 31 140 were assigned to the colonoscopy group, 60 300 to the faecal immunochemical test group, and 186 840 to the control group. 10 679 (35.1%) of 30 400 people who received an invitation for colonoscopy participated. 33 383 (55.5%) of 60 137 people who received a postal faecal immunochemical test participated. In the intention-to-screen analysis, colorectal cancer was detected in 49 (0.16%) of 31140 people in the colonoscopy group versus 121 (0. 20%) of 60 300 in the faecal immunochemical test group (relative risk [RR] 0.78, 95% CI 0.56-1.09). Advanced adenomas were detected in 637 (2.05%) people in the colonoscopy group and 968 (1.61%) in the faecal immunochemical test group (RR 1.27, 95% CI 1.15-1.41). Colonoscopy detected more right-sided advanced adenomas than faecal immunochemical testing. There were two perforations and 15 major bleeds in 16 555 colonoscopies. No intervention-related deaths occurred. Interpretation The diagnostic yield and the low number of adverse events indicate that the design from this trial, both for once-only colonoscopy and faecal immunochemical test screening, could be transferred to a population-based screening service if a benefit in disease-specific mortality is subsequently shown. Copyright (C) 2022 Elsevier Ltd. All rights reserved.
650 7a MEDICIN OCH HÄLSOVETENSKAPx Klinisk medicinx Cancer och onkologi0 (SwePub)302032 hsv//swe
650 7a MEDICAL AND HEALTH SCIENCESx Clinical Medicinex Cancer and Oncology0 (SwePub)302032 hsv//eng
7001 a Westerberg, Marcusu Uppsala Univ, Sweden4 aut
7001 a Metcalfe, Chrisu Univ Bristol, England4 aut
7001 a Steele, Robertu Univ Dundee, Scotland4 aut
7001 a Blom, Johannesu Karolinska Institutet,Soder Sjukhuset, Sweden; Soder Sjukhuset, Sweden4 aut
7001 a Engstrand, Larsu Karolinska Institutet,Karolinska Inst, Sweden; Karolinska Inst, Sweden4 aut
7001 a Fritzell, Kaisau Karolinska Institutet,Karolinska Inst, Sweden; Karolinska Inst, Sweden4 aut
7001 a Hellstrom, Mikaelu Gothenburg Univ, Sweden; Sahlgrens Univ Hosp, Sweden4 aut
7001 a Levin, Lars-Åkeu Linköpings universitet,Avdelningen för samhälle och hälsa,Medicinska fakulteten4 aut0 (Swepub:liu)larle77
7001 a Lowbeer, Christianu Karolinska Inst, Sweden; SYNLAB Medilab, Sweden4 aut
7001 a Pischel, Andreasu Univ Gothenburg, Sweden4 aut
7001 a Stromberg, Ulfu Univ Gothenburg, Sweden4 aut
7001 a Tornberg, Svenu Karolinska Institutet,Karolinska Inst, Sweden4 aut
7001 a Wengstrom, Yvonneu Karolinska Institutet,Karolinska Inst, Sweden; Karolinska Inst, Sweden; Karolinska Univ Hosp, Sweden4 aut
7001 a Ekbom, Andersu Karolinska Institutet,Soder Sjukhuset, Sweden4 aut
7001 a Holmberg, Larsu Uppsala Univ, Sweden; Kings Coll London, England4 aut
7001 a Hultcrantz, Rolfu Soder Sjukhuset, Sweden4 aut
7102 a Karolinska Institutetb Soder Sjukhuset, Sweden4 org
7730 t The Lancet Gastroenterology & Hepatologyd : ELSEVIER INCg 7:6, s. 513-521q 7:6<513-521x 2468-1253
8564 8u https://urn.kb.se/resolve?urn=urn:nbn:se:liu:diva-187549
8564 8u https://doi.org/10.1016/S2468-1253(21)00473-8
8564 8u http://kipublications.ki.se/Default.aspx?queryparsed=id:150324585

Hitta via bibliotek

Till lärosätets databas

Kungliga biblioteket hanterar dina personuppgifter i enlighet med EU:s dataskyddsförordning (2018), GDPR. Läs mer om hur det funkar här.
Så här hanterar KB dina uppgifter vid användning av denna tjänst.

 
pil uppåt Stäng

Kopiera och spara länken för att återkomma till aktuell vy